1 October 2020 in Journal of Investigative Dermatology
1 January 2021 in Oxidative Medicine and Cellular Longevity
T‐cell malignancies are still difficult to treat due to a paucity of plans that target critical dependencies. Drug‐induced cellular senescence provides a permanent cell cycle arrest during tumorigenesis and cancer development, particularly when combined with senolytics to promote apoptosis of senescent cells, which is an innovation for cancer therapy. Here, our research found that wogonin, a well‐known natural flavonoid compound, not only had a potential to inhibit cell growth and proliferation but also induced cellular senescence in T‐cell malignancies with nonlethal concentration. Transcription activity of senescence‐suppression human telomerase reverse transcriptase (hTERT) and oncogenic C-MYC was suppressed in wogonin‐induced senescent cells, resulting in the inhibition of telomerase activity. We also substantiated the occurrence of DNA damage during the wogonin‐induced aging process. Results showed that wogonin increased the activity of senescence‐associated β‐galactosidase (SA‐β‐Gal) and activated the DNA damage response pathway mediated by p53. In addition, we found the upregulated expression of BCL‐2 in senescent T‐cell malignancies because of the antiapoptotic properties of senescent cells. Following up this result, we identified a BCL‐2 inhibitor Navitoclax (ABT‐263), which was highly effective in decreasing cell viability and inducing apoptotic cell death in wogonin‐induced senescent cells. Thus, the “one‐two punch” approach increased the sensibility of T‐cell malignancies with low expression of BCL‐2 to Navitoclax. In conclusion, our research revealed that wogonin possesses potential antitumor effects based on senescence induction, offering a better insight into the development of novel therapeutic methods for T‐cell malignancies.
30 September 2022 in Medical Research
The important of survival motor neurone gene (SMN) was first realized when deletions or mutations in the SMN1 gene were found to cause Spinal Muscular Atrophy(SMA).But the relationship of SMN1 and cancers was not clear. In our study, We evaluated the role of SMN1 in esophageal cancer using publicly available data from The Cancer Genome Atlas (TCGA). we found that high level of SMN1 in esophageal cancer predicted poor prognosis. SMN1 expression may be a potential prognostic molecular marker of poor survival in esophageal cancer, Moreover, proteasome pathway and phosphatidylinositol signaling system regulated by SMN1 in esophageal cancer.
15 January 2022 in Trends Journal of Sciences Research
Background. Guanylate cyclase 1 soluble subunit alpha 2 (sGCα2), also known as GUCY1A2, was reported to be upregulated and promoted tumorigenesis in cervical cancer. But whether GUCY1A2 was abnormally expressed and its prognostic value in gastric cancer was unknown. The current study aimed to find out the prognostic value of GUCY1A2 in gastric cancer by analyzing data from The Cancer Genome Atlas (TCGA) database. Methods. Wilcoxon signed-rank test, cox regression analysis and multivariant analysis were used to analyze the relationship between clinical characteristic and GUCY1A2 expression level. Kaplan-Meier method was used to analyze the association of GUCY1A2 and overall survival. Gene set enrichment analysis (GSEA) was used to identify GUCY1A2-related signaling pathway. Results. Compared to normal tissue, expression of GUCY1A2 was significantly increased in gastric cancer (p<0.001). Increased GUCY1A2 was associated with advanced T stage (p=0.012) and poor survival (p=0.022). Univariate analysis showed that high GUCY1A2 expression was associated with a poor overall survival (HR:1.44, 95% confidence interval [CI]: 1.03-2.02, p=0.03). Multivariate analysis indicated that GUCY1A3 remained an independent prognostic predictor of overall survival (HR:1.75, 95% confidence interval [CI]: 1.20-2.56, p=0.00). GSEA revealed that calcium signaling pathway, MAPK signaling pathway, TGF-β signaling pathway and Wnt signaling pathway were enriched in GUCY1A2 high expression phenotype. Conclusions. GUCY1A2 maybe a potential prognostic predictor of poor survival in gastric cancer. But it need to be further validated clinically.